New Staging Tool for Cutaneous T-cell Lymphoma (PROBEinCTCL) +++++ ++++

CLINICAL PERSPECTIVES Hemolytic Disease of the Fetus and Newborn: Outcomes of Intrauterine Transfusion and Patient Experiences https://checkrare.com/hemolytic-disease-of-the-fetus-and-newborn-outcomes-of-intrauterine-transfusion-and-patient-experiences/ May Lee Tjoa, PhD, Senior Global Medical Affairs Leader: Nipocalimab and Maternal-Fetal Immunology at Johnson & Johnson, discusses data on hemolytic disease of the fetus and newborn (HDFN) from the 2025 ISUOG World Congress on Ultrasound in Obstetrics and Gynecology. Rilzabrutinib Approval for Adult Patients With Immune Thrombocytopenia https://checkrare.com/rilzabrutinib-approval-for-adult-patients-with-immune-thrombocytopenia/ Amit Mehta, MD, Medical Oncologist, discusses data that led to the approval of Wayrilz (rilzabrutinib) for adult patients with immune thrombocytopenia (ITP). ISUOG World Congress 2025: Hemolytic Disease of the Fetus and Newborn https://checkrare.com/isuog-world-congress-2025-hemolytic-disease-of-the-fetus-and-newborn/ Jannine Williams, Compound Development Team Leader at Johnson & Johnson, discusses key takeaways from studies on hemolytic disease of the fetus and newborn (HDFN) presented at ISUOG World Congress 2025. Plans for Phase 2/3 Clinical Trial of Bexmarilimab Plus Standard of Care in Patients With Myelodysplastic Syndromes https://checkrare.com/plans-for-phase-2-3-clinical-trial-of-bexmarilimab-plus-standard-of-care-in-patients-with-myelodysplastic-syndromes/ Amer Zeidan, MBBS, MHS, Professor of Internal Medicine at Yale School of Medicine and Chief of the Division of Hematologic Malignancies at Yale Cancer Center, discusses plans for a phase 2/3 clinical trial testing bexmarilimab plus standard of care in patients with myelodysplastic syndromes (MDS). Results From the LINKER-SMM1 Trial in Patients With High-Risk Smoldering Multiple Myeloma https://checkrare.com/results-from-the-linker-smm1-trial-in-patients-with-high-risk-smoldering-multiple-myeloma/ Paula Rodriguez Otero, MD, PhD, Hematologist at the University of Navarra, discusses results from the LINKER-SMM1 trial in patients with high-risk smoldering multiple myeloma (HR-SMM). New Staging Tool for Cutaneous T-cell Lymphoma (PROBEinCTCL) https://checkrare.com/new-staging-tool-for-cutaneous-t-cell-lymphoma-probeinctcl/ Greg Palko, Vice President and Oncology Franchise Head of Kyowa Kirin North America, discusses a new cutaneous T-cell lymphoma (CTCL) Staging Tool. Diagnosing and Treating a Patient With Castleman Disease https://checkrare.com/diagnosing-and-treating-a-patient-with-castleman-disease/ Robin Williams, MD, Pediatric Hematology Oncologist at M Health Fairview Masonic Children’s Hospital, discusses her experience diagnosing and treating a patient with Castleman disease (CD). Clinical Experience With Iptacopan for Treatment of PNH https://checkrare.com/clinical-experience-with-iptacopan-for-treatment-of-pnh/ Jamie Koprivnikar, MD, Hematologist Oncologist at Hackensack University Medical Center, discusses her clinical experience with iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Linvoseltamab in the Treatment of Relapsed/Refractory Multiple Myeloma https://checkrare.com/linvoseltamab-in-the-treatment-of-relapsed-refractory-multiple-myeloma/ Joshua Richter, MD, Associate Professor of Medicine at the Tisch Cancer Institute, Director of Multiple Myeloma at the Blavatnik Family- Chelsea Medical Center at Mount Sinai, discusses the recent U.S. Food and Drug Administration (FDA) approval of linvoseltamab for the treatment of relapsed/refractory multiple myeloma (MM).